@article{a6024ada5c5f4bebb03c9628579a75ff,
title = "Craving and opioid use disorder: A scoping review",
abstract = "Introduction: The subjective experience of drug craving is a prominent and common clinical phenomenon for many individuals diagnosed with opioid use disorder (OUD), and could be a valuable clinical endpoint in medication development studies. The purpose of this scoping review is to provide an overview and critical analysis of opioid craving assessments located in the published literature examining OUD. Method: Studies were identified through a search of PubMed, Embase, and PsychInfo databases and included for review if opioid craving was the focus and participants were diagnosed with or in treatment for OUD. Results: Fifteen opioid craving assessment instruments were identified across the 87 studies included for review. The most common were the Visual Analog Scale (VAS, 41 studies), Desires for Drug Questionnaire (DDQ, 12 studies), Heroin Craving Questionnaire (HCQ, 10 studies), and Obsessive-Compulsive Drug Use Scale (OCDUS, 10 studies). Craving assessments varied considerably in their format, content, time frame, and underlying subscales, and only 6 of 15 had been psychometrically evaluated. Discussion: This review identified a variety of opioid craving assessments, but few had been evaluated for their psychometric properties making it difficult to ascertain whether craving is being assessed optimally in studies of OUD. Thus, the development of a reliable and valid opioid craving assessment would be worthwhile and could be guided by recently published Food and Drug Administration Clinical Outcome Assessment (COA) guidelines. Importantly, a COA focused on opioid craving could be a valuable addition to research studies designed to evaluate novel treatments for OUD.",
keywords = "Craving, Dependence, Opioid, Opioid use disorder, Outcomes",
author = "Kleykamp, {Bethea A.} and {De Santis}, Marta and Dworkin, {Robert H.} and Huhn, {Andrew S.} and Kampman, {Kyle M.} and Montoya, {Ivan D.} and Preston, {Kenzie L.} and Tanya Ramey and Smith, {Shannon M.} and Turk, {Dennis C.} and Robert Walsh and Weiss, {Roger D.} and Strain, {Eric C.}",
note = "Funding Information: Financial support for this project was provided by the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) a public-private partnership with the US Food and Drug Administration (FDA) (U01-FD005936), which has received research grants, contracts, and other support from the FDA, multiple pharmaceutical and device companies, philanthropy, royalties, and other sources (a list of ACTTION's industry sponsors is available at http://www.acttion.org/partners). Funding Information: Financial support for this project was provided by the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) a public-private partnership with the US Food and Drug Administration (FDA) ( U01-FD005936 ), which has received research grants, contracts, and other support from the FDA, multiple pharmaceutical and device companies, philanthropy, royalties, and other sources (a list of ACTTION{\textquoteright}s industry sponsors is available at http://www.acttion.org/partners ). Funding Information: Bethea Kleykamp completed all literature searches and data extraction and wrote the first draft of the manuscript. All authors contributed to the writing and have approved the final manuscript. We thank Valorie Thompson for her assistance in organizing the meeting on which this article is based; Katrina Foster, PhD, Shwe Gyaw, MD, Allison H. Lin, PharmD, PhD, Robert Schwartz, MD, David McCann, PhD, and Celia Winchell, MD for their valuable participation; and Linda Hasman, at the University of Rochester, for her guidance in designing the literature search strategy. The contents of this manuscript have not been copyrighted or published previously. The contents of this manuscript are not under consideration for publication elsewhere. The contents of this manuscript will not be copyrighted, submitted, or published elsewhere while acceptance by the Journal is under consideration. Robert H. Dworkin, PhD, has received in the past 36 months research grants and contracts from US Food and Drug Administration and US National Institutes of Health, and compensation for consulting on clinical trial methods from Abide, Acadia, Adynxx, Analgesic Solutions, Aptinyx, Aquinox, Asahi Kasei, Astellas, AstraZeneca, Biogen, Biohaven, Boston Scientific, Braeburn, Celgene, Centrexion, Chromocell, Clexio, Concert, Decibel, Dong-A, Eli Lilly, Eupraxia, Glenmark, Grace, Hope, Immune, Lotus Clinical Research, Mainstay, Neumentum, Neuroana, NeuroBo, Novaremed, Novartis, Olatec, Pfizer, Phosphagenics, Quark, Reckitt Benckiser, Regenacy (also equity), Relmada, Sanifit, Scilex, Semnur, Sollis, Teva, Theranexus, Trevena, Vertex, and Vizuri. Dennis C. Turk, PhD, has received in the past 36 months research grants and contracts from US Food and Drug Administration and US National Institutes of Health, and Patient Centered Outcomes Research Institute (PCORI) and compensation for consulting on research methods from: AccelRx, Eli Lilly, Johnson and Johnson, GlaxoSmithKline, Novartis, Pfizer, and St. Jude Publisher Copyright: {\textcopyright} 2019 Elsevier B.V.",
year = "2019",
month = dec,
day = "1",
doi = "10.1016/j.drugalcdep.2019.107639",
language = "English (US)",
volume = "205",
journal = "Drug and Alcohol Dependence",
issn = "0376-8716",
publisher = "Elsevier Ireland Ltd",
}